Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas

Simple item page
dc.contributor.authorGarudadri, Gen_US
dc.contributor.authorRao, BVen_US
dc.contributor.authorSundaram, Cen_US
dc.contributor.authorFonseca, Den_US
dc.contributor.authorMurthy, SSen_US
dc.contributor.authorSharma, Ren_US
dc.contributor.authorRao, TSen_US
dc.date.accessioned2020-04-10T01:51:23Z
dc.date.available2020-04-10T01:51:23Z
dc.date.issued2020-02
dc.description.abstractContext: The diagnosis of prostatic adenocarcinoma on histopathology depends on architectural and cytomorphological features supported by immunohistochemistry (IHC). Though all the prostate markers show excellent specificity, the sensitivity and percentage positivity vary. Aims: In this study, we aim to study the expression of prostein in normal, benign, and malignant (primary and metastatic) lesions with particular emphasis on its utility in the differential diagnosis of poorly differentiated and metastatic prostatic adenocarcinoma along with a standard panel of IHC markers. Settings and Design: This was both a prospective and retrospective as well as descriptive and observational study. Subjects and Methods: All samples from patients with clinically suspected carcinoma prostate from both primary and metastatic sites from June 2015 to May 2016 were included in the study. Samples with difficulty in diagnosis on hematoxylin and eosin staining were subjected to a panel of IHC markers along with prostein. Statistical Analysis Used: Receiver operating curve analysis and Chi-square test. Results: Prostein showed a 100% sensitivity and specificity to identify normal prostatic epithelium, benign and premalignant lesions, and prostatic adenocarcinoma. Prostein showed a specificity of 100% in differentiating prostatic carcinoma from poorly differentiated urothelial carcinoma and in differentiating metastatic prostatic carcinoma from adenocarcinoma of nonprostatic origin. Conclusions: Prostein is a new and promising prostate-specific marker that showed slightly more sensitivity and specificity than prostate-specific antigen. Thus, adding prostein to the IHC panel will greatly improve the detection of poorly differentiated primary and metastatic lesions of the prostate.en_US
dc.identifier.affiliationsDepartment of Pathology and Lab Medicine, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, Indiaen_US
dc.identifier.affiliationsDepartment of Surgical Oncology, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, Telangana, Indiaen_US
dc.identifier.citationGarudadri G, Rao BV, Sundaram C, Fonseca D, Murthy SS, Sharma R, Rao TS. Diagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomas. Indian Journal of Pathology and Microbiology. 2020 Feb; 63(5): 18-24en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/196485
dc.languageenen_US
dc.publisherIndian Association of Pathologists and Microbiologistsen_US
dc.relation.issuenumber5en_US
dc.relation.volume63en_US
dc.source.urihttps://dx.doi.org/10.4103/IJPM.IJPM_852_18en_US
dc.subjectImmunohistochemistryen_US
dc.subjectprostate adenocarcinomaen_US
dc.subjectprosteinen_US
dc.titleDiagnostic utility of immunohistochemical marker prostein for evaluation of primary and metastatic prostatic carcinomasen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijpm2020v63n5p18.pdf
Size:
1.84 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology